Journal
EMERGING INFECTIOUS DISEASES
Volume 21, Issue 6, Pages 977-983Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2106.141329
Keywords
-
Categories
Funding
- US Agency for International Development
- CDC
- National Institutes of Health's National Institute of Allergy and Infectious Diseases, Division of Intramural Research and South Korea's Center for Disease Control
Ask authors/readers for more resources
Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5-6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2-4) drugs; 26% retained susceptibility to <= 2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available